Eczematous eruption during anti‐interleukin 17 treatment of psoriasis: an emerging condition

Abstract

Major advances in psoriasis pathogenesis gave rise to development of new effective drugs for its treatment. Particularly, biologic drugs revolutionized disease management. TNF‐α inhibitors represented the opening available biologic class since 2000. Thus, adverse cutaneous reactions to their use have been extensively investigated.

This article is protected by copyright. All rights reserved.

http://bit.ly/2TMUj9k